Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?
Retail traders are piling into Novavax on cancer-vaccine speculation, but the move that actually changed the company's business model happened quietly last week and has nothing to do with oncology.